Alnylam Pharmaceuticals/ALNY

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.

Ticker

ALNY

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

Headquarters

Cambridge, United States

Employees

2,100

ALNY Metrics

BasicAdvanced
$19B
Market cap
-
P/E ratio
-$2.71
EPS
0.30
Beta
-
Dividend rate
$19B
0.3
$218.88
$141.98
12
3.174
3.074
-1.37%
-9.20%
-11.86%
9.372
146.884
75.20%
68.87%
54.80%

What the Analysts think about ALNY

Analyst Ratings

Majority rating from 29 analysts.
Buy

ALNY Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-13.33% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$494M
12.42%
Net income
-$66M
-52.18%
Profit margin
-13.33%
-57.45%

ALNY Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 56.04%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$2.21
$1.15
-$1.10
-$0.52
-
Expected
-$1.37
-$1.34
-$1.32
-$1.18
-$1.11
Surprise
61.47%
-186.09%
-16.84%
-56.04%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Alnylam Pharmaceuticals stock?

Alnylam Pharmaceuticals (ALNY) has a market cap of $19B as of June 25, 2024.

What is the P/E ratio for Alnylam Pharmaceuticals stock?

The price to earnings (P/E) ratio for Alnylam Pharmaceuticals (ALNY) stock is 0 as of June 25, 2024.

Does Alnylam Pharmaceuticals stock pay dividends?

No, Alnylam Pharmaceuticals (ALNY) stock does not pay dividends to its shareholders as of June 25, 2024.

When is the next Alnylam Pharmaceuticals dividend payment date?

Alnylam Pharmaceuticals (ALNY) stock does not pay dividends to its shareholders.

What is the beta indicator for Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (ALNY) has a beta rating of 0.3. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Alnylam Pharmaceuticals stock

Buy or sell Alnylam Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing